Experimental red blood cell therapy for advanced cancer
Part of Blood & lymphatic, Cancer clinical trials.
This early-phase trial tests an experimental immunotherapy for people with advanced solid tumors who have not benefited from standard treatments. The treatment involves attaching a cancer-fighting drug to your own red blood cells, and the study will check if it's safe and if it might shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced cancer that has spread or cannot be removed by surgery.
- You have tried standard treatments, or there is no effective standard treatment available, or you chose not to have standard treatment.
- You are in reasonably good health, able to care for yourself, and expected to live at least 3 more months.
- You are willing to use effective birth control for the study period and 3 months after the last dose.
- You do not have active bleeding or blood clotting disorders, nor a history of blood clots.
- You do not have significant lung damage, lung fibrosis, or a history of treatment-related lung inflammation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized cell therapy (CAR-NK) using donor immune cells that are engineered to find and attack one or two markers on advanced solid tumors. It may be an option for people whose tumors have these specific markers and have exhausted other treatments.
This study tests a new type of cell therapy called anti-HER2-CAR-T for people with advanced HER2-positive solid tumors (like breast, stomach, or colon cancer) whose cancer has not responded to other treatments. The therapy uses your own immune cells engineered to target and kill cancer cells.
This study tests a new immunotherapy using specially engineered immune cells (called TCR-enhanced Vδ2 T cells) to treat blood cancers or solid tumors that haven't responded to standard treatments. The goal is to see if these cells can safely shrink tumors and improve survival.
This early-phase study (Phase 1) tests Hemay181, a new cancer medicine, in people with advanced solid tumors that have not been controlled by standard treatment. The goal is to see how the medicine works in the body and whether it can shrink or control tumors safely.
This trial tests a new immune cell therapy for people with advanced solid tumors (lung, liver, colorectal, or breast cancer). It aims to use your own immune cells to fight the cancer, and might help if standard treatments have stopped working.
This trial tests a new type of cell therapy (CAR-T and targeted DC cells) for people with advanced solid tumors that have specific proteins. It aims to see if these immune cells can shrink tumors or slow their growth.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.